Skip to main content
. 2022 Jun 13;42(9):1629–1637. doi: 10.1097/IAE.0000000000003556

Fig. 2.

Fig. 2.

Recommendations for assessment, patient education, and management for IOI after brolucizumab based on the authors' opinions. Anterior uveitis, intermediate uveitis, and posterior uveitis are defined according to the SUN working group.34